Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.
The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.
Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced a technical error in its website that led to an unrelated poster presentation being displayed on the Corporate Presentations page. The company clarified that the correct presentation of its breast cancer vaccine clinical trial from the 2023 AACR Annual Meeting can be found on the Events page of its website. Anixa focuses on cancer treatment and prevention, collaborating with renowned institutions like Moffitt Cancer Center and Cleveland Clinic for its innovative therapies, including CAR-T technology and vaccines targeting triple negative breast cancer and ovarian cancer.
Anixa Biosciences (NASDAQ: ANIX) announced positive data from a Phase 1 trial of its breast cancer vaccine presented by the Cleveland Clinic. The data showed that immune responses were observed at all dose levels in vaccinated women, indicating varying levels of antigen-specific T cell responses. The trial aims to assess the vaccine's safety, determine the Maximum Tolerated Dose (MTD), and monitor immune responses in women at high risk of recurrence after having triple negative breast cancer (TNBC). Dr. Amit Kumar, CEO of Anixa, expressed optimism regarding the results, while Dr. G. Thomas Budd noted that the trial is not designed to confirm the efficacy of preventing recurrence. This promising development holds potential for future studies and advancements in breast cancer treatment.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced that it will present results from its Phase 1a breast cancer vaccine trial on April 17, 2023, at the American Association for Cancer Research Annual Meeting in Orlando, FL. The vaccine, targeting triple-negative breast cancer using α-lactalbumin, is designed to activate the immune system against cancer cells expressing this 'retired' protein. This presentation will be significant for stakeholders following advancements in cancer immunotherapy. Anixa's portfolio also includes ovarian cancer immunotherapy programs in collaboration with Moffitt Cancer Center.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced it has no accounts at the recently collapsed Silicon Valley Bank, providing reassurance to shareholders and the investment community. The company focuses on cancer treatment and prevention, with ongoing projects in ovarian and breast cancer immunotherapy. Anixa partners with renowned research institutions like Moffitt Cancer Center and Cleveland Clinic to advance its novel CAR-T and vaccine technologies. These initiatives aim to target specific cancer types, particularly the aggressive triple-negative breast cancer and ovarian cancer.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
What does Anixa Biosciences specialize in?
What are the key components of Anixa's therapeutic portfolio?
What recent achievements has Anixa Biosciences announced?
Who are some of Anixa Biosciences' key collaborators?
How does Anixa's CER-T technology differ from traditional CAR-T therapies?
What is unique about Anixa's cancer vaccine technology?
Which forms of cancer are Anixa's vaccines targeting?
What are some recent clinical trial results from Anixa?
Does Anixa Biosciences participate in industry conferences?
Where can I find more information about Anixa Biosciences?
